Abstract:Cancer immunotherapy with ICB is considered a promising strategy for cancer treatment. In silico prediction of the ICB response is an important step toward achieving effective and personalized cancer immunotherapy. Three challenging issues remain: (i) Identifying highly predictive biomarkers by deciphering and understanding the interaction between tumor and immune cells; (ii) efficiently obtaining and predicting these biomarkers using HTS data; and (iii) building effective computational models that integrate these biomarkers for improved ICB response prediction. Cancer immunotherapy with immune-checkpoint blockade (ICB) is considered a promising strategy for cancer treatment. Identifying predictive biomarkers and developing efficient computational models to predict the ICB response are important issues for successful immunotherapy. Here, we present a concise and intuitive survey of the computational issues for ICB response prediction, providing a summary of the available predictive biomarkers and building of one-stop machine-learning models that integrate biomarkers calculable from high-throughput sequencing (HTS) data. Several points for discussion are highlighted to inspire further research for improving ICB treatment. Continuing efforts are required to improve ICB response prediction and to identify novel predictive biomarkers by taking advantage of the rapid development of computational models and HTS techniques for effective and personalized cancer immunotherapy. Cancer immunotherapy with immune-checkpoint blockade (ICB) is considered a promising strategy for cancer treatment. Identifying predictive biomarkers and developing efficient computational models to predict the ICB response are important issues for successful immunotherapy. Here, we present a concise and intuitive survey of the computational issues for ICB response prediction, providing a summary of the available predictive biomarkers and building of one-stop machine-learning models that integrate biomarkers calculable from high-throughput sequencing (HTS) data. Several points for discussion are highlighted to inspire further research for improving ICB treatment. Continuing efforts are required to improve ICB response prediction and to identify novel predictive biomarkers by taking advantage of the rapid development of computational models and HTS techniques for effective and personalized cancer immunotherapy. immune checkpoints are molecules in the immune system that either enhance or attenuate a signal. Tumors protect themselves from the immune system by inhibiting the T cell signal. The use of inhibitors to block inhibitory checkpoint molecules by recovering the anticancer immune response is referred to as ‘immune checkpoint blockade’. peptides presented by MHC class I or MHC class II molecules on the tumor cell surface. These peptides derive from tumor-specific somatic mutations and are not expressed in normal cells. the cellular environment in which the tumor exists, including surrounding blood vessels, immune cells, fibroblasts, bone marrow-derived inflammatory cells, lymphocytes, signaling molecules, and the extracellular matrix. The tumor and surrounding microenvironment are closely related and constantly interact. Effective immunotherapy often requires changes to the TME. V-J recombination is the unique mechanism of genetic recombination that occurs in developing lymphocytes during the early stages of T and B cell maturation. It involves somatic recombination in a nearly random fashion, which rearranges variable (V), joining (J), and, in some cases, diversity (D) gene segments. This has resulted in the highly diverse repertoire of antibodies and/or immunoglobulins (Igs) and T cell receptors (TCRs) found on B cells and T cells, respectively.

The Rigidity of a Structural Bridge on HLA-I Binding Groove Explains Its Differential Outcome in Cancer Immune Response.

Patient HLA Class I Genotype Influences Cancer Response to Checkpoint Blockade Immunotherapy

Impact of HLA-DR Antigen Binding Cleft Rigidity on T Cell Recognition

Altered Ligand-Interaction Contributes to Functional Insufficiency Due to CTLA-4 Gene Mutation

Germline HLA-B Evolutionary Divergence Influences the Efficacy of Immune Checkpoint Blockade Therapy in Gastrointestinal Cancer

Integrated germline and somatic features reveal divergent immune pathways driving ICB response

In silico design of high-affinity antigenic peptides for HLA-B44

Germline HLA-B Evolutionary Divergence to Influence Efficacy of Immune Checkpoint Blockade Therapy in Gastrointestinal Cancer.

Microenvironmental factors shape resistance patterns to immune checkpoint blockade

Abstract 3779: Clonal Tracing Reveals Different Mechanisms of Resistance to Immune Checkpoint Blockade

Conserved Immuno‐collagenic Subtypes Predict Response to Immune Checkpoint Blockade

Towards in Silico Prediction of the Immune-Checkpoint Blockade Response

Molecular basis of differential HLA class I-restricted T cell recognition of a highly networked HIV peptide

Polymorphic residues in HLA-B that mediate HIV control distinctly modulate peptide interactions with both TCR and KIR molecules

The Heterogeneity of Genomic Biomarkers for Immune Checkpoint Inhibitor in Therapy-Naïve Primary Hepatocellular Carcinoma and Their Metachronous Metastases.

Immune Cell Densities Predict Response to Immune Checkpoint-Blockade in Head and Neck Cancer

Abstract 1204: Neoantigen MHC presentability ratios influence the tumor microenvironment and response to immunotherapy

Abstract 5378: Spatially resolved human leukocyte antigen (HLA) expression correlates with motif neoepitope expression and durable response to immune checkpoint blockade (ICB) in non-small cell lung cancer (NSCLC)

Identification of the Core Regulators of the Hla I-Peptide Binding Process

Structural insights into the binding of hepatitis B virus core peptide to HLA-A2 alleles: towards designing better vaccines.

HLA genotyping meets response to immune checkpoint inhibitors prediction: A story just started